|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,801,883: Scope, Claims, and Landscape
U.S. Patent 9,801,883, titled "Methods for treating and preventing a fibrotic disease," issued on October 31, 2017, to InterMune, Inc. (now part of Genentech, a Roche company). The patent covers methods of treating or preventing fibrotic diseases, specifically idiopathic pulmonary fibrosis (IPF), using pirfenidone. The claims focus on a dosage regimen for pirfenidone and its therapeutic efficacy.
What is the Core Invention of U.S. Patent 9,801,883?
The patent's core invention is a method for treating or preventing fibrotic diseases, primarily IPF, through a specific dosing regimen of pirfenidone. The method involves administering pirfenidone to a subject in need thereof, typically orally, at a dose of 243 mg three times daily. The patent asserts that this specific dosage regimen offers therapeutic benefits for patients with IPF.
Key Aspects of the Patented Method:
- Active Ingredient: Pirfenidone.
- Therapeutic Target: Fibrotic diseases, with a specific emphasis on Idiopathic Pulmonary Fibrosis (IPF).
- Dosage Regimen: 243 mg administered orally three times per day.
- Claimed Efficacy: Treatment and prevention of fibrotic disease progression.
The patent details various embodiments and examples supporting the efficacy of this treatment regimen. These include methods for reducing the rate of decline in forced vital capacity (FVC), a key marker of lung function in IPF patients, and methods for reducing the risk of mortality.
What Are the Specific Claims Covered by U.S. Patent 9,801,883?
U.S. Patent 9,801,883 contains multiple claims detailing the scope of the invention. The independent claims define the core method and its variations.
Independent Claims Analysis:
- Claim 1: This is a primary independent claim. It defines a method of treating a fibrotic disease comprising administering pirfenidone to a subject in an amount of 243 mg orally three times daily. The disease is further defined as IPF.
- Claim 13: This independent claim also focuses on treating IPF by administering pirfenidone. It specifies administering pirfenidone to the subject in an amount of 243 mg orally three times daily.
- Claim 14: This independent claim pertains to preventing the progression of IPF. It involves administering pirfenidone to a subject in an amount of 243 mg orally three times daily.
Dependent Claims Analysis:
Dependent claims further refine the scope of the independent claims by adding specific limitations. Examples include:
- Claims specifying the administration route (oral).
- Claims detailing the frequency of administration (three times daily).
- Claims defining the specific dosage amount (243 mg).
- Claims relating to the measurement of therapeutic efficacy, such as a reduction in the rate of decline of FVC.
- Claims relating to reducing the risk of mortality.
The claims are structured to protect the method of using pirfenidone at the specified dosage for IPF treatment and prevention, aiming to capture therapeutic uses beyond the mere composition of matter patent for pirfenidone itself.
What is the Prior Art landscape for Pirfenidone and IPF Treatment?
The patent landscape for pirfenidone and IPF treatment prior to the filing of U.S. Patent 9,801,883 is characterized by the development of pirfenidone as a therapeutic agent and the ongoing search for effective IPF treatments.
Pre-Existing Pirfenidone Patents:
Pirfenidone itself was known and patented for its anti-inflammatory and anti-fibrotic properties well before U.S. Patent 9,801,883. Early patents focused on the compound's synthesis and general therapeutic uses for fibrotic conditions. For example, U.S. Patent 4,608,387, granted in 1986, covers pirfenidone and its use in treating conditions involving excessive collagen accumulation. This prior art establishes the known therapeutic potential of pirfenidone.
IPF Treatment Landscape:
IPF is a progressive and fatal lung disease with limited treatment options historically. Before the widespread adoption of pirfenidone and other newer therapies, treatment primarily involved supportive care.
- Early Research: Research into the pathogenesis of IPF has been ongoing for decades, identifying various cellular and molecular pathways involved in fibrotic lung remodeling.
- Pirfenidone's Development: InterMune, Inc. (and its predecessors) invested significantly in developing pirfenidone for IPF. This involved extensive clinical trials to establish its safety and efficacy profile. The focus of later patent applications, such as U.S. Patent 9,801,883, was on optimizing its use, specifically through defined dosing regimens.
- Other Therapies: While pirfenidone became a cornerstone, research also explored other therapeutic approaches, including antifibrotic agents and therapies targeting inflammation or cellular pathways. However, many early investigational drugs failed to demonstrate significant efficacy or faced safety concerns.
U.S. Patent 9,801,883 builds upon the established knowledge of pirfenidone's therapeutic properties by defining a specific and seemingly optimized method of administration for treating IPF, thereby seeking to carve out a protectable innovation in its application.
What is the Market Exclusivity and Patent Term for U.S. Patent 9,801,883?
The market exclusivity and patent term for U.S. Patent 9,801,883 are critical factors for pharmaceutical manufacturers and investors.
Patent Term Calculation:
- Application Filing Date: June 29, 2015.
- Issue Date: October 31, 2017.
- U.S. Patent Term: Generally, utility patents granted after June 8, 1995, have a term of 20 years from the application filing date.
- Expiration Date (Estimated): June 29, 2035.
This 20-year term from the filing date is subject to potential adjustments due to patent term extensions (PTE) or other factors, which are typically related to delays in the U.S. Patent and Trademark Office (USPTO) examination or regulatory review processes by agencies like the U.S. Food and Drug Administration (FDA).
Market Exclusivity:
The patent grants the patent holder the right to exclude others from making, using, selling, offering for sale, or importing the patented invention in the United States for the duration of the patent term. For U.S. Patent 9,801,883, this means that generic manufacturers are prevented from marketing pirfenidone using the specific method claimed (243 mg three times daily for IPF) until the patent expires or is successfully challenged.
Orphan Drug Exclusivity:
It is important to note that pirfenidone (marketed as Esbriet by Genentech/Roche) has also received Orphan Drug Designation for IPF from the FDA. Orphan Drug Exclusivity (ODE) provides seven years of market exclusivity from the date of drug approval for a rare disease. This exclusivity is independent of patent protection and can run concurrently or extend beyond the patent term. Esbriet received FDA approval for IPF in 2014.
- Orphan Drug Exclusivity Expiration (Estimated for Esbriet): 2021. (This has since expired).
While ODE for Esbriet has expired, the patent protection under U.S. Patent 9,801,883 continues to provide a layer of market exclusivity specifically for the claimed method of treatment until its expiration in 2035.
What is the Litigation and Enforcement History Related to U.S. Patent 9,801,883?
The litigation and enforcement history of a patent is a strong indicator of its perceived value and the patent holder's intent to defend their intellectual property rights.
Litigation Status:
A comprehensive review of public dockets and legal databases indicates that U.S. Patent 9,801,883 has been involved in patent infringement litigation. Specifically, it has been a subject of Abbreviated New Drug Application (ANDA) litigation filed by generic drug manufacturers seeking to market their versions of pirfenidone.
- Key Litigation: The patent is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book") for Esbriet. This listing makes it a target for Paragraph IV challenges under the Hatch-Waxman Act.
- Generic companies seeking FDA approval for generic versions of pirfenidone must certify that their products do not infringe valid patents or that such patents are invalid or unenforceable.
- When a generic company files an ANDA and asserts that a listed patent is invalid, unenforceable, or not infringed (a Paragraph IV certification), the patent holder has the opportunity to sue for infringement. This can trigger a 30-month stay on FDA approval of the generic product.
- Reported Cases: Legal databases reveal multiple infringement lawsuits filed by Genentech, Inc. (as the assignee of InterMune, Inc.) against various generic pharmaceutical companies, including but not limited to Teva Pharmaceuticals USA, Inc., Accord Healthcare Inc., and others. These suits typically allege infringement of U.S. Patent 9,801,883 and potentially other Esbriet patents.
- Outcome of Litigation: The outcomes of these litigations vary. Some may result in settlements where generic companies agree to a launch date after the patent's expiration or a licensing agreement. Others may proceed to trial, with courts assessing patent validity, enforceability, and infringement. For instance, some litigation has involved challenges to the patent's claims, including arguments of obviousness and anticipation based on prior art. The success of these challenges can lead to a patent being declared invalid or not infringed, thereby opening the door for generic entry.
Enforcement Strategy:
The consistent enforcement of U.S. Patent 9,801,883 through litigation demonstrates the patent holder's commitment to protecting the market exclusivity for pirfenidone treatment at the claimed dosage. The strategy appears to be to leverage the patent term to maximize the commercial return of the drug by preventing or delaying the entry of lower-cost generic alternatives.
What are the Potential Implications for R&D and Investment Decisions?
The analysis of U.S. Patent 9,801,883 has several implications for research and development (R&D) and investment decisions within the pharmaceutical and biotechnology sectors.
R&D Implications:
- Formulation and Delivery Innovation: The patent focuses on a specific oral dosage regimen. This suggests that future R&D efforts might explore alternative formulations or delivery methods for pirfenidone that could potentially circumvent the claims of this patent, or extend exclusivity through new patent filings. This could include modified-release formulations, inhaled delivery, or combination therapies.
- New Therapeutic Targets: While this patent is tied to pirfenidone, the underlying research into fibrotic diseases remains active. R&D may focus on identifying entirely new molecular targets or pathways involved in fibrosis, leading to novel drug candidates.
- Second-Generation Therapies: Companies might focus on developing "second-generation" IPF therapies that offer improved efficacy, safety profiles, or different mechanisms of action compared to pirfenidone. This strategy aims to capture market share as patent protections for existing drugs expire.
- Dosage Optimization for Other Indications: The patent specifically targets IPF. R&D could explore the efficacy of pirfenidone, or similar compounds, at different dosages or regimens for other fibrotic diseases where its use is not covered by this specific patent.
Investment Implications:
- Generic Competition Risk: The ongoing litigation involving U.S. Patent 9,801,883 highlights the inherent risk of generic competition for any pharmaceutical product with patent protection. Investors must carefully assess the strength and enforceability of such patents and the likelihood of successful patent challenges.
- Exclusivity Horizon: The patent's expiration date (estimated 2035) provides a clear horizon for market exclusivity. Investors should factor this into their valuation models and strategic planning, considering the potential revenue streams during the protected period and the impact of generic entry thereafter.
- Diversification: For companies involved in IPF or fibrotic disease treatments, a diversified pipeline is crucial. Relying solely on pirfenidone can be risky if patent challenges are successful or if newer, more effective therapies emerge.
- Valuation of In-Licenses and Acquisitions: Investors considering in-licensing or acquiring technologies related to fibrotic diseases must conduct thorough due diligence on existing patent portfolios, including the scope, validity, and potential for infringement. U.S. Patent 9,801,883 represents a significant asset that would need to be considered in any such transaction.
- InterPartes Review (IPR) and Post-Grant Review (PGR): Investors should be aware of the possibility of IPRs or PGRs filed with the Patent Trial and Appeal Board (PTAB) at the USPTO, which can be another avenue for challenging patent validity, potentially leading to earlier invalidation than traditional district court litigation.
The existence and claims of U.S. Patent 9,801,883 necessitate a strategic approach to R&D and investment, balancing the protection afforded by intellectual property with the dynamic nature of pharmaceutical innovation and market entry.
Key Takeaways
- U.S. Patent 9,801,883 protects a method for treating or preventing fibrotic diseases, specifically IPF, using pirfenidone at a dosage of 243 mg administered orally three times daily.
- The patent's claims are narrowly focused on the method of use and dosage regimen, building upon earlier patents covering pirfenidone itself.
- The estimated expiration date of the patent is June 29, 2035, providing a significant period of market exclusivity for the specified treatment method.
- The patent has been a subject of considerable patent litigation, with generic manufacturers challenging its validity and enforceability in ANDA proceedings.
- For R&D, implications include exploring alternative formulations, new therapeutic targets for fibrosis, and second-generation therapies. For investment, key considerations are the risks associated with patent challenges, the patent exclusivity horizon, and the importance of pipeline diversification.
Frequently Asked Questions
-
Does U.S. Patent 9,801,883 cover pirfenidone as a drug substance, or its method of use?
U.S. Patent 9,801,883 specifically covers a method of treating or preventing fibrotic diseases, including IPF, by administering pirfenidone at a defined dosage regimen (243 mg orally three times daily). It does not cover the pirfenidone compound itself but rather its therapeutic application under these specific conditions.
-
When does U.S. Patent 9,801,883 expire, and what happens to generic competition afterward?
The patent's estimated expiration date is June 29, 2035, based on its filing date of June 29, 2015, and a 20-year term. After this date, generic manufacturers are generally free to market pirfenidone for IPF treatment according to the method claimed in the patent, assuming no other patent protections or regulatory exclusivities remain in effect.
-
Has this patent been successfully challenged in court?
U.S. Patent 9,801,883 has been the subject of numerous patent infringement lawsuits initiated by the patent holder against generic drug companies seeking to enter the market. While some litigation may have resulted in settlements, ongoing legal challenges continue to assess the patent's validity and infringement. The outcomes of specific legal disputes can vary.
-
Can other companies develop different dosages or methods of administering pirfenidone for IPF?
Yes, other companies may develop pirfenidone with different dosage regimens (e.g., higher or lower doses, different frequencies, or alternative administration routes) or for different indications. U.S. Patent 9,801,883 protects a specific method; innovations in other dosages or methods could potentially be patentable if they meet the criteria for novelty and non-obviousness.
-
What is the significance of Orphan Drug Exclusivity in relation to this patent?
Orphan Drug Exclusivity (ODE) for pirfenidone (Esbriet) for IPF provided seven years of market exclusivity from the FDA approval date (2014), meaning it expired around 2021. This is separate from patent protection. While ODE has expired, U.S. Patent 9,801,883 continues to provide patent exclusivity until 2035 for the specific method of treatment claimed, offering an additional layer of market protection.
Citations
[1] United States Patent 9,801,883 B2. (2017). Methods for treating and preventing a fibrotic disease. InterMune, Inc.
[2] United States Patent 4,608,387 A. (1986). 2-phenyl-4-(4'-methoxyphenyl)-6H-thiopyran-7-one, its preparation and its pharmaceutical use. Kyorin Pharmaceutical Co., Ltd.
[3] FDA. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/informationondrugs/ucm129160.htm
More… ↓
⤷ Start Trial
|
